CXCR4 Receptor as a Promising Target for Oncolytic Drugs

Author(s): Yan Lavrovsky, Yan A. Ivanenkov, Konstantin V. Balakin, Darya A. Medvedeva, Alexandre V. Ivachtchenko

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 8 , Issue 11 , 2008

Become EABM
Become Reviewer
Call for Editor


There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.

Keywords: Chemokine, chemokine receptor, CXCR4, CXCL12, SDF-1, tumor, cancer, drugs, inhibitors, antagonists

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [1075 - 1087]
Pages: 13
DOI: 10.2174/138955708785909907
Price: $65

Article Metrics

PDF: 3